Figures computed from official regulatory filings — .
Analysttarget 262.5 USD (+5450%)
Ownershipinsiders 2.04% · institutions 0.02% · short 5.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Jaguar Health, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
11 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| MICEK JOHN | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MICEK JOHN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CONTE LISA Atrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wolin Jonathan S. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wolin Jonathan S. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CONTE LISA Atrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| King Steven R. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| King Steven R. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jayasuriya Anula | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lizak Carol R. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jayasuriya Anula | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BOCHNOWSKI JAMES Jtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Siegel Jonathan B.track record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lizak Carol R. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BOCHNOWSKI JAMES Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chaturvedi Pravin R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chaturvedi Pravin R | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Siegel Jonathan B.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chaturvedi Pravin R | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| MICEK JOHN | OtherD (derivative) | $450M | SEC |
| Wolin Jonathan S. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| MICEK JOHN | AwardD (derivative) | $473.1M | Unusual size | SEC |
| Siegel Jonathan B.track record | OtherD (derivative) | $450M | SEC |
| Siegel Jonathan B.track record | AwardD (derivative) | $473.1M | SEC |
| MICEK JOHN | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |